This week, we’ll be discussing a study that examined rates of breakthrough COVID-19 infection in vaccinated health-care workers. Then, we’ll move on to a report that compared the efficacy of different durations of anastrozole treatment in patients with hormone receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy.

Coverage of stories discussed this week on ascopost.com:

Breakthrough COVID-19 Infection in Fully Vaccinated Health-Care Workers

Outcomes With 2 vs 5 Years of Hormone Therapy Following Adjuvant Endocrine Therapy in Postmenopausal Women With HR-Positive Breast Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.